



## **Media Statement**

### **CSL ANNOUNCES LICENCE TO MARKET AND DISTRIBUTE POPULAR DERMATOLOGY RANGE FROM INTENDIS**

German-based company, Intendis GmbH (a subsidiary of Schering AG) has granted CSL Limited an exclusive license to market and distribute three of their better known products in Australia.

The products include Advantan™, a topical corticosteroid for the treatment of eczema; Finacea™, for the treatment of rosacea and acne; and Scheriproct™, used in the treatment of haemorrhoids.

‘This new arrangement offers an excellent fit with CSL’s existing in-licensed product range’, CSL’s Sales and Marketing Director Dr John Anderson said today.

‘It allows CSL to offer more comprehensive support to Australian dermatologists and general practitioners across a wider variety of disease states’ Dr Anderson said.

All products are currently marketed in Australia and will be further supported through sales and marketing efforts alongside other CSL products in the dermatology portfolio.

**For further information please contact:**

**Dr Rachel David**  
**Director, Public Affairs CSL Ltd**  
**Ph 0401 775 779.**